Ratings Amgen Inc. Buenos Aires S.E.

Equities

AMGN

ARDEUT110665

End-of-day quote Buenos Aires S.E. Other stock markets 18:00:00 2024-05-21 EDT			5-day change	1st Jan Change
12,890 ^ARS	+2.77%		+10.48%	+38.11%

05-22	Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	CF
05-22	Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.91 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
AMGEN INC.	+38.11%	166B	-
ELI LILLY AND COMPANY	+39.73%	723B	C+
NOVO NORDISK A/S	+34.28%	595B	B
JOHNSON & JOHNSON	-4.06%	369B	C+
MERCK & CO., INC.	+20.36%	332B	B-
ABBVIE INC.	+2.95%	282B	C+
ASTRAZENECA PLC	+17.02%	244B	B+
NOVARTIS AG	+9.31%	208B	B-
ROCHE HOLDING AG	-5.07%	205B	A+
PFIZER, INC.	+0.03%	168B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes